Stocksigma LogoStocksigma Logo

Molbio Diagnostics Q2 FY27 Consolidated Results And Key Board Outcomes

Molbio Diagnostics reported consolidated revenue from operations of ₹2,590.20 million for the quarter ended 30th Sep'26, down from ₹4,083.76 million in the

Molbio Diagnostics Q2 FY27 Consolidated Results And Key Board Outcomes

Molbio Diagnostics Ltd · Outcome · 05 Nov 2026, 11:03 pm

Molbio Diagnostics Q2 FY27 Consolidated Results And Key Board Outcomes Molbio Diagnostics reported consolidated revenue from operations of ₹2,590.20 million for the quarter ended 30th Sep'26, down from ₹4,083.76 million in the preceding quarter. Net profit stood at ₹77.01 million compared to ₹527.44 million in Q1 FY27, with diluted EPS at ₹1.33. For H1 FY27, consolidated revenue reached ₹6,673.96 million with PAT of ₹604.45 million. Additionally, the board approved the IPO Monitoring Agency Report, noted the resignation of President & CMO Dr. Kuldeep Singh Sachdeva effective 21st Jan'27, and appointed secretarial auditors.

Original exchange filing (PDF)

More announcements from Molbio Diagnostics Ltd

All Molbio Diagnostics Ltd announcements